№ files_lp_3_process_7_076282
File format: docx
Character count: 2704
File size: 51 KB
Official WTO sanitary and phytosanitary notification issued by South Africa concerning the prohibition of agricultural remedies containing chlorpyrifos and cartap hydrochloride under national legislation regulating fertilizers, farm feeds and agricultural remedies.
Notifying Member:
South Africa
Responsible Agency:
Department of Agriculture, Land Reform and Rural Development
Products Covered:
Agricultural remedies (pesticides)
Active Substances:
Chlorpyrifos; Cartap hydrochloride
Legal Basis:
Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947)
Objective:
Food safety
International Standard:
None
Affected Regions:
All trading partners
Related Publication:
Government Gazette No. 48847 dated 26 June 2023
Proposed Adoption Date:
After consideration of comments
Proposed Publication Date:
After consideration of comments
Proposed Entry into Force:
Six months from date of publication
Final Date for Comments:
15 September 2023
Designated Authority for Comments:
National Enquiry Point, Department of Agriculture, Land Reform and Rural Development
Contact Address:
Private Bag X343, Pretoria, 0001, 20 Steve Biko Street
Telephone:
+27 12 319 7303
Email:
[email protected]
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
1967-1976
Region / City:
United States
Topic:
Pesticide Studies, Mosquito and Cockroach Control
Document Type:
Research Bibliography
Organization / Institution:
Office of Pesticide Programs
Author:
Various
Target Audience:
Researchers, Pesticide Program Administrators
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2016
Region / City:
Yola, Adamawa State, Nigeria
Theme:
Environmental Science, Microbiology, Agricultural Chemistry
Document Type:
Research Article
Organization / Institution:
Modibbo Adama University of Technology, Yola
Author:
Ajunwa, O.M, Audu, J.O, Adedeji, B.A, Ja’afaru, M.I
Target Audience:
Researchers, Environmental Scientists, Agricultural Chemists
Period of Validity:
Not applicable
Approval Date:
Not applicable
Modification Date:
Not applicable
Year:
2026
Region / city:
Europe
Topic:
Pharmaceutical Product Information
Document Type:
Medical Product Information
Institution:
European Medicines Agency
Author:
European Medicines Agency
Target Audience:
Healthcare professionals
Period of validity:
Ongoing
Approval Date:
2026
Date of Changes:
2026
Year:
2021
Region / City:
Australia
Topic:
Pharmaceutical submission
Document type:
Submission report
Organization:
Novartis Pharmaceuticals Australia Pty Limited
Author:
Novartis Pharmaceuticals Australia Pty Limited
Target audience:
Healthcare professionals, regulatory bodies
Period of validity:
Ongoing
Approval date:
21 August 2002
Date of revisions:
18 December 2009, 11 March 2016, 8 July 2021, 16 July 2021, 29 July 2021
Note:
Contextual description
Year:
2019
Region / city:
Saint-Cloud Cedex, France
Topic:
Medicine information
Document type:
Prescribing Information
Organization / institution:
Ethypharm
Author:
Not specified
Target audience:
Healthcare professionals
Effective period:
Not specified
Approval date:
December 2019
Amendment date:
Not specified
Contraindications:
Hypersensitivity to diltiazem, sick sinus syndrome, severe bradycardia, and others
Warnings and precautions:
Monitor patients with reduced left ventricular function, bradycardia, and others
Interactions:
Dantrolene, Ivabradine, and others
Side effects:
Peripheral oedema, atrioventricular block, dizziness, and others
Product License Number:
PL 06934/0195
Marketing Authorization Number:
PL 06934/0195
Legal Category:
POM
Description:
Information document regarding Angitil capsules for managing angina pectoris and hypertension, including dosage, contraindications, interactions, and side effects.
Year:
2019
Region / City:
Kathmandu, Nepal
Field:
Pharmaceutical Sciences
Document Type:
Research Article
Institution:
Central Institute of Science and Technology
Authors:
Maharjan S, Pradhan A, Shrestha M, Koju S
Target Audience:
Researchers, healthcare professionals
Period of Validity:
Ongoing
Approval Date:
2019
Date of Last Modification:
Not specified
Department:
Not specified
Date SOP was written:
Not specified
Date SOP was approved by PI/Lab Supervisor:
Not specified
Principal Investigator:
Not specified
Internal Lab Safety Coordinator/Lab Manager:
Not specified
Institution:
University of Georgia
Chemical Name:
Amiodarone hydrochloride
CAS Number:
19774-82-4
Molecular Formula:
C25H29I2NO3·HCl
Chemical Class:
Irritant, Toxic
Physical State:
Solid
Recommended Storage Temperature:
2–8 °C
Type of SOP:
Hazardous Chemical
Related Policy Documents:
UGA Chemical and Laboratory Safety Manual; UGA Respiratory Protection Plan
Emergency Contact Procedures:
Dial 911; Campus emergency numbers provided
Intended Use:
Laboratory handling and safety compliance
Year:
Not specified
Region / Country:
Pakistan
Cities:
Multan; Sahiwal
Field:
Pharmaceutical analysis; Analytical chemistry; Pharmaceutics
Document Type:
Scientific research article
Institutions:
Drug Testing Laboratory Government of Punjab; Bahauddin Zakariya University Faculty of Pharmacy; Quaid-e-Azam College of Pharmacy
Authors:
Rao Khurram Ayoub; Syed Nisar Hussain Shah; Asma Aslam; Romana Riaz; Naveed Nisar; Shakeel Ijaz; Aousaf Ahmad; Muneeb Ahmad
Corresponding Author:
Syed Nisar Hussain Shah
Affiliation of Corresponding Author:
Department of Pharmaceutics Faculty of Pharmacy Bahauddin Zakariya University Multan Pakistan; Quaid-e-Azam College of Pharmacy Sahiwal Punjab Pakistan
Keywords:
HPLC; Famotidine; Drotaverine; Ondansetron; Central composite design
Analyzed Compounds:
Ondansetron Dihydrochloride; Famotidine; Drotaverine Hydrochloride
Experimental Model:
Rabbit plasma
Methodology:
High-performance liquid chromatography with central composite design optimization
Mobile Phase Composition:
Acetonitrile and phosphate buffer pH 4.8 (40:60 v/v)
Flow Rate:
1.5 mL/min
Replication:
Six experimental replicates
Contact Email:
[email protected]
Contact Phone:
+92-334-7315016
Year:
2018
Region / city:
Australia
Subject:
Pharmaceutical application for diabetes treatment
Document type:
Pharmaceutical submission
Organization / institution:
PBAC, TGA
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical practitioners, healthcare professionals
Validity period:
Ongoing since 2018
Approval date:
16 April 2018
Revision date:
March 2018
Year:
2024
Date:
September 20, 2024
Subject:
Adverse effects of chemotherapy medications
Medications:
Cyclophosphamide; Topotecan Hydrochloride
Document Type:
Medical safety information sheet
Category:
Drug side effects classification
Frequency Categories:
Common; Occasional; Rare and serious
Population Described:
Patients receiving Cyclophosphamide and Topotecan Hydrochloride
Medical Context:
Chemotherapy treatment
Content Elements:
Infection risk, blood disorders, gastrointestinal symptoms, reproductive effects, organ damage, allergic reactions, secondary cancer risk
Health Conditions Mentioned:
Anemia; heart failure; kidney damage; lung damage; sinusoidal obstructive syndrome; Stevens-Johnson syndrome; leukemia